Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Curative Inc., a leading health services company that recently launched a new health plan out of Texas, announces the spin-off of Sensible Diagnostics, whose aim is to commercialize their groundbreaking point-of-care PCR testing platform.

Stockholm, Sweden-based Devyser Diagnostics on Monday announced that it has inked a collaboration and distribution agreement that gives Thermo Fisher Scientific the exclusive rights to commercialize its post-transplant portfolio of next-generation sequencing (NGS) products in North America and Europe.

On April 18, Sino Biological Inc., a protein and antibody R&D and production expert, signed a strategic cooperation agreement with Megarobo.

A large population-based cohort study has linked COVID-19 to increased risk of diabetes, adding to the evidence that SARS-CoV-2 infection may contribute to the development of the metabolic disorder.

BioMérieux and JMI Laboratories announced that they have entered a six-year project to evaluate the performance of tests for antimicrobial resistance.

On October 17, 2020, the 22nd meeting of the Standing Committee of the 13th National People's Congress voted to adopt the Biosafety Law, which will come into force on April 15, 2021.

Abbott announced financial results for the first quarter ended March 31, 2023.

The World Health Organization on Wednesday issued a new standard for countries implementing rapid diagnostics to detect tuberculosis. The guidelines are the first-ever WHO has issued for rapid TB testing.

The penetration rate of blood glucose meters among diabetes patients in China is far lower than that in developed countries, and there is a huge market space for blood glucose meters.

UK circulating tumor cell firm Angle said Wednesday that it has signed an agreement with BioView to develop a liquid biopsy HER2 assay using its cell isolation technology, Parsortix, and BioView's automated microscopy systems and software.